WindMIL Therapeutics
Signal active
Organization
Contact Information
Overview
WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients. The company leveraging its proprietary platform to develop a novel class of cell therapies called MILs (Marrow Infiltrating Lymphocytes) derived from memory T cells found in the bone marrow.
WindMIL Therapeutics was established in 2015 and is based in Baltimore, MD.
About
Industries
Biotechnology, Medical Device, Therapeutics
Founded
2015
Employees
11-50
Headquarters locations
Princeton, New Jersey, United States, North America
Social
Profile Resume
WindMIL Therapeutics headquartered in United States, North America, operates in the Biotechnology, Medical Device, Therapeutics sector. The company focuses on Biotechnology and has secured $1.0B in funding across 24 round(s). With a team of 11-50 employees, WindMIL Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - WindMIL Therapeutics, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
1
Lead Investors
0
Total Funding Amount
$42.5M
Details
2
WindMIL Therapeutics has raised a total of $42.5M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 32.5M | ||
| 2016 | Early Stage Venture | 10.0M |
Investors
WindMIL Therapeutics is funded by 11 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| WindMIL Therapeutics | - | FUNDING ROUND - WindMIL Therapeutics | 32.5M |
| FoxKiser | - | FUNDING ROUND - FoxKiser | 32.5M |
| WindMIL Therapeutics | - | FUNDING ROUND - WindMIL Therapeutics | 10.0M |
| Scott H. Cohen | - | FUNDING ROUND - Scott H. Cohen | 10.0M |